Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CEL
Creative Medical Technology Holdings
CELZ · NASDAQ · Biological Products, (No Diagnostic Substances)
Creative Medical Technology Holdings (CELZ) · oqro.io/stocks/CELZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Creative Medical Technology Holdings insider trading
Have Creative Medical Technology Holdings insiders bought shares recently?
No open-market purchase by an insider of Creative Medical Technology Holdings was filed in the last 90 days. The latest on record was on Jun 28, 2023.
How often do Creative Medical Technology Holdings insiders buy and sell shares?
Since 2016, Creative Medical Technology Holdings insiders reported 23 open-market purchases and 22 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2023.
Who is selling Creative Medical Technology Holdings stock?
No open-market sale by an insider of Creative Medical Technology Holdings (CELZ) was filed with the SEC in the last 90 days.
Do members of Congress trade CELZ?
No trade in Creative Medical Technology Holdings (CELZ) was disclosed by a member of Congress in the last 12 months.
When does Creative Medical Technology Holdings report its next results?
Creative Medical Technology Holdings's next results are expected on Mar 18, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Insiders who traded Creative Medical Technology Holdings
−85.3% (−$2.33) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $2.73 on Nov 20, 2025 to $0.4025 on Nov 20, 2026 (−85.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$0.00$1.00$1.50$2.00$2.50$3.00$0.4025
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Phoenix, Az.
Last 12 months
−85.3%
S&P 500 +5.7% over the same dates
Market value
$3.06M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 66K shares sold short (0.9% of shares outstanding), −19.4% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $6.85M, at Sep 30, 2026
Net income, last 12 months
−$7.47M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
No Schedule 13D or 13G filing on CELZ over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Late-stage clinical trials
0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in chronic low-back pain, type 1 diabetes. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
From “Overview”, in the company's words
We are a commercial stage biotechnology company dedicated to the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016.
What the section covers (5 headings)
Overview
Off-Balance Sheet Arrangements
Liquidity and Capital Resources
Net Cash from Financing Activities
Critical Accounting Policies and Estimates
Source: SEC EDGAR, Form 10-K filed Mar 20, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Creative Medical Technology Holdings filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $8.1K, in 1 filing). (Creative Medical Technology Holdings on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chron..." (Phase 2, status active not recruiting), was updated on Aug 21, 2026, with primary completion listed for 2027-01-20. FINRA short interest for CELZ on the settlement date of Oct 30, 2026 was 66,165 shares (-19.36% on the previous report), about 1 days of average volume.
Company reports, price and press. Creative Medical Technology Holdings filed a Form 8-K on Nov 13, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange. Creative Medical Technology Holdings filed a Form 8-K on Sep 25, 2026 (Items 1.01, 3.02) that OQRO classes as: signed an important agreement, and sold new shares without registering them.
Who holds it. 13 funds reported a stake in Creative Medical Technology Holdings in their 13F for Q2 2026. The largest by value: Hudson Bay Capital Management LP (36.3% of the value reported), Anson Funds Management LP (28.3% of the value reported), ARMISTICE CAPITAL, LLC (11.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Creative Medical Technology Holdings filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $8.1K, in 1 filing).
Contracts, lobbying and filings
ClinicalTrials.gov shows 2 studys sponsored by the company updated in the period; the latest, "Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chron..." (Phase 2, status active not recruiting), was updated on Aug 21, 2026, with primary completion listed for 2027-01-20.
FINRA short interest for CELZ on the settlement date of Oct 30, 2026 was 66,165 shares (-19.36% on the previous report), about 1 days of average volume.
Company reports, price and press
Creative Medical Technology Holdings filed a Form 8-K on Nov 13, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
Creative Medical Technology Holdings filed a Form 8-K on Sep 25, 2026 (Items 1.01, 3.02) that OQRO classes as: signed an important agreement, and sold new shares without registering them.
Creative Medical Technology Holdings filed a Form 8-K on Jul 2, 2026 (Items 1.01, 3.02, 5.02) that OQRO classes as: changed a top executive or board member, and signed an important agreement (and 1 more item).
The company's own opening sentence of that report reads: "On July 1, 2026, the Compensation Committee of the Company’s Board of Directors approved the payment of a bonus to Timothy Warbington, the Company’s Chief Executive Officer, in the amount of $100,000."
Press coverage listed by Finnhub: "Creative Medical Technology Highlights Ultrasome Data Showing 93% Response Rate, 65% Pain Reduction In Knee Osteoarthritis Study" (Benzinga, Oct 20, 2026).
Press coverage listed by Finnhub: "Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%" (Benzinga, Sep 25, 2026).
Press coverage listed by Finnhub: "Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing" (Yahoo, Sep 17, 2026).
CELZ closed at $0.4663 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.7236 to $0.4663, a change of −35.6%.
Who holds it
13 funds reported a stake in Creative Medical Technology Holdings in their 13F for Q2 2026. The largest by value: Hudson Bay Capital Management LP (36.3% of the value reported), Anson Funds Management LP (28.3% of the value reported), ARMISTICE CAPITAL, LLC (11.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Creative Medical Technology Holdings's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Creative Medical Technology Holdings's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 47.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (0.9% on ATS, 46.4% with other brokers), below its 26-week average of 62.2%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: BOATS (17.9%), IBKR ATS (14.1%), UBS ATS (10.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Mar 20, 2026, compared with the one filed Mar 14, 2025. Read the filing
All 32 risk factor headings match the year before, give or take wording.
Legal proceedings (Item 3)
From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
Source: SEC EDGAR, Form 10-K filed Mar 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Insider buying and selling since 2016
Insiders of Creative Medical Technology Holdings reported 23 open-market purchases and 22 sales since 2016; purchases in 3 different years, most recently 2023.
Year
Bought
Sold
2025
—
$8.1K2×2 trades
2023
$4.4K4×4 trades
—
2022
$85K16×16 trades
—
2021
—
$131K
3×3 trades
2017
—
$11K12×12 trades
2016
$160K3×3 trades
$75.5B5×5 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Nov 13
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
On the public record for Creative Medical Technology Holdings over the 12 months to Nov 21, 2026: 2 clinical trials.